http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 27 Oct 2026 17:28:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Protagonist+Therapeutics+++++++++++++++Filed+by%3A+BlackRock%2C+Inc./27242657.html si-local-file:///var/storage/secattach/20261027/27242657.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Protagonist+Therapeutics+++++++++++++++Filed+by%3A+BlackRock%2C+Inc./27242657.html Tue, 27 Oct 2026 17:28:00 -0400 PTGX http://www.streetinsider.com/Press+Releases/Protagonist+Therapeutics+to+Participate+in+Four+Investment+Bank+Conferences+in+November+2026/27236520.html <p><strong id="dateline">NEWARK, CA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / October 27, 2026 / </strong>Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today announced that senior management will participate in four investment bank conferences taking place in November 2026.</p><p><strong>8^th Annual Wolfe Research Healthcare Conference</strong><br />Format: Fireside Chat and 1x1 meetings<br />Date: Tuesday, November 10, 2026<br />Time: 1:20 - 1:50 p.m. EST<br />Location: New York, NY</p><p><strong>Truist Securities 2026 Biopharma Symposium</strong><br />Format: 1x1 meetings<br />Date: Thursday, November 12, 2026<br />Location: New York, NY</p><p><strong>UBS Global Biopharma Conference</strong><br />Format: Fireside Chat and 1x1 meetings<br />Date: Monday, November 16, 2026<br />Time: 12:40 http://www.streetinsider.com/Press+Releases/Protagonist+Therapeutics+to+Participate+in+Four+Investment+Bank+Conferences+in+November+2026/27236520.html Tue, 27 Oct 2026 07:00:00 -0400 PTGX http://www.streetinsider.com/ACCESS+Newswire/Protagonist+Therapeutics+to+Participate+in+Four+Investment+Bank+Conferences+in+November+2026/27236520.html <p><strong id="dateline">NEWARK, CA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / October 27, 2026 / </strong>Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today announced that senior management will participate in four investment bank conferences taking place in November 2026.</p><p><strong>8^th Annual Wolfe Research Healthcare Conference</strong><br />Format: Fireside Chat and 1x1 meetings<br />Date: Tuesday, November 10, 2026<br />Time: 1:20 - 1:50 p.m. EST<br />Location: New York, NY</p><p><strong>Truist Securities 2026 Biopharma Symposium</strong><br />Format: 1x1 meetings<br />Date: Thursday, November 12, 2026<br />Location: New York, NY</p><p><strong>UBS Global Biopharma Conference</strong><br />Format: Fireside Chat and 1x1 meetings<br />Date: Monday, November 16, 2026<br />Time: 12:40 http://www.streetinsider.com/ACCESS+Newswire/Protagonist+Therapeutics+to+Participate+in+Four+Investment+Bank+Conferences+in+November+2026/27236520.html Tue, 27 Oct 2026 07:00:00 -0400 PTGX http://www.streetinsider.com/Analyst+PT+Change/Protagonist+Therapeutics+%28PTGX%29+PT+Raised+to+%24160+at+TD+Cowen/27213511.html TD Cowen analyst Tara Bancroft raised the price target on Protagonist Therapeutics (NASDAQ: PTGX) to $160.00 (from $155.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Protagonist+Therapeutics+%28PTGX%29+PT+Raised+to+%24160+at+TD+Cowen/27213511.html Wed, 21 Oct 2026 08:12:24 -0400 PTGX http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR